A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Talazoparib (Primary) ; Temozolomide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 07 Nov 2019 Planned End Date changed from 1 Nov 2020 to 1 Nov 2021.
- 07 Nov 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.
- 10 Sep 2019 Results (as of 8 March 2019: n=3) assessing safety and tolerability of talazoparib plus temozolomide in patients with relapsed or refractory of extensice stage small cell lung cancer, presented at the 20th World Conference on Lung Cancer.